DailyMed
Cure8 regulatory brief
DailyMed label update for AMJEVITA
Medications
Adalimumab
Anti-TNF
Biosimilars
Regulatory Update
Adult patients
Pediatric Patients
Clinicians
Why This Matters
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety warnings such as infection and malignancy risks.
That information guides prescribing, monitoring, and informed discussions with clinicians.
Who Should Pay Attention
Adult and pediatric patients with Crohn's disease or ulcerative colitis; patients using or considering adalimumab biosimilars; clinicians and pharmacists who prescribe or dispense biologics; caregivers of pediatric patients.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Source depthMetadata only
What To Know
This is a DailyMed prescribing information (label) update for AMJEVITA (adalimumab-atto), a biosimilar to HUMIRA.
The label lists approved indications, dosing (including induction and maintenance regimens for Crohn's disease and ulcerative colitis, and pediatric dosing), boxed warnings for serious infections and malignancy, recent major changes to indications and dosing (10/2025), and other prescribing details.
Read the full FDA-approved prescribing information or discuss with your clinician for individualized treatment decisions. This note summarizes what the updated label presents and is not medical advice.
Key sections in the label include indications and usage, dosage and administration (with Crohn's and UC induction/maintenance dosing and pediatric schedules), warnings/precautions (serious infections, TB screening, malignancy risk), and dosage forms/strengths.
Patients should consult their prescriber or pharmacist for practical questions about dosing, monitoring, pregnancy, or switching between adalimumab products.
Keep In Mind
This entry is an official DailyMed (FDA‑label) update summarizing the approved prescribing information. Labels describe regulatory‑approved indications and safety warnings but do not replace individualized clinical advice. For specific questions about switching products, pregnancy, immunizations, or monitoring, consult your health care team.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationDailyMed
Study typeDrug Label Update
Indexed viaDailyMed
Source typeDrug label record
PublishedJul 20, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
ABRILADA FDA label update (2026-06-18)
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.